Dr. Tawbi on the Efficacy of Relatlimab/Nivolumab in Advanced Melanoma

Source: OncLive, June 2021

Hussein A. Tawbi, MD, PhD, the deputy chair of the Department of Melanoma Medical Oncology, Division of Cancer Medicine; the director of Melanoma Clinical Research and Early Drug Development, Department of Melanoma Medical Oncology, Division of Cancer Medicine; the director of Personalized Cancer Therapy, Department of Melanoma Medical Oncology, Division of Cancer Medicine; and a professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the efficacy of relatlimab plus nivolumab (Opdivo; Opdualag) in patients with advanced melanoma.

READ THE ORIGINAL FULL ARTICLE